Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Luc Heraudet"'
Autor:
Luc Heraudet, Tara Delon, Rémi Veillon, Charlotte Vergnenègre, Hélène Lepetit, Amaury Daste, Alain Ravaud, Maéva Zysman, Charlotte Domblides
Publikováno v:
Thoracic Cancer, Vol 13, Iss 9, Pp 1391-1400 (2022)
Abstract Background The effect of the sequential combination of chemotherapy and immune checkpoint inhibitors (ICIs) remains unclear. Here, we evaluated the efficacy of different chemotherapy regimens administered after ICIs in advanced non‐small c
Externí odkaz:
https://doaj.org/article/f58fb57ae7b34b96b2fc76259ec5eb96
Autor:
Mathieu Larroquette, Félix Lefort, Luc Heraudet, Jean-Christophe Bernhard, Alain Ravaud, Charlotte Domblides, Marine Gross-Goupil
Publikováno v:
Cancers. 14(24)
Clear cell renal cell carcinoma (RCC) oncogenesis is mainly driven by VHL gene inactivation, leading to overexpression of vascular endothelial growth factor (VEGF). The use of tyrosine-kinase inhibitors (TKIs) directed against VEGF and its receptor (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e644fb67d1abd7f4537327bff005b38b
https://pubmed.ncbi.nlm.nih.gov/36551715
https://pubmed.ncbi.nlm.nih.gov/36551715
Autor:
Luc Heraudet, Jean Galtier, Simon Favre, Florent Peyraud, Titouan Cazaubiel, Harmony Leroy, Nathan Mottal, François‐Xavier Gros, Edouard Forcade, Laurence Clément, Pierre‐Yves Dumas, Arnaud Pigneux, Thibaut Leguay
Publikováno v:
British journal of haematologyREFERENCES. 198(3)
Adults with relapsed or refractory B-precursor acute lymphoblastic leukaemia (R/R BCP-ALL) have very poor outcome. Blinatumomab as single agent has shown activity in R/R BCP-ALL. We aimed to assess the activity of blinatumomab in concomitant associat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18c348e2e3229a2430f1cec17c99670d
https://pubmed.ncbi.nlm.nih.gov/35524489
https://pubmed.ncbi.nlm.nih.gov/35524489
Autor:
Luc Heraudet, Alain Ravaud, Amaury Daste, Félix Lefort, Jean-Christophe Bernhard, Charlotte Domblides, Marine Gross-Goupil
Publikováno v:
Expert Opinion on Drug Safety. 19:799-806
The safety profile characteristics of sunitinib were evaluated in patients who underwent nephrectomy for kidney cancer.In this literature review, safety data were evaluated from phase III trials investigating sunitinib following nephrectomy, either i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fd7e982ef27840d8268faf841f15d61
https://doi.org/10.1080/14740338.2020.1774551
https://doi.org/10.1080/14740338.2020.1774551
Publikováno v:
European Journal of Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a18b33321142db80baaedaacb316c8cd
https://doi.org/10.1016/j.ejca.2020.04.039
https://doi.org/10.1016/j.ejca.2020.04.039